Taken together, our data strongly suggest that Mcl-1 upregulation is likely a key resistance mechanism to Everolimus in BRAF600E cells (Figure 6E), while other CRC drivers including the gatekeeper APC mutation might strongly influence Everolimus sensitivity. The gene discussed is APC; the disease is colorectal carcinoma.